Enabling
Regenerative Medicine
Our ApoGraft™ technology turns production of stem cells into a simple, safe and inexpensive process
Learn more about CellectOur ApoGraft™ technology turns production of stem cells into a simple, safe and inexpensive process
Learn more about CellectJAN 2017
US Patent
Notice of Allowance
FEB 2017
First Cancer Patient Treated In Phase I/II Trial
Positive Clinical Results
MAR 2017
Successful First Cancer Patient Stem Cell Transplant
JUN 2017
Cellect Receives
Russian Patent
SEP 2017
FDA Grants Cellect Orphan Drug Status for ApoGraft™
JAN 2018
Positive Clinical Trial Results
100% Acceptance and Zero Related Adverse Events
JAN 2018
Opening 2nd Clinical Trial Site
DSMB Approves Dose Escalation
APR 2018
Successfully completes POC testing for scalable production of ApoTainer™
JUL 2018
Signs Collaboration Agreement with Dresden University
AUG 2018
Cellect Granted Key European Patent for Stem Cells Selection Technology
AUG 2018
Korean Patent
Notice of Allowance
It is all about replacing damaged tissues and organs instead of "fixing" them with drugs and radiations
The process takes weeks in specialty labs, remains highly ineffective and its costs keep stem cell treatments a privilege of the elitist-few who can afford it
